JSR Life Sciences to expand KBI Biopharma and Selexis’ biologics manufacturing capabilities

This article was originally published here

With a combined area of 8,700m² in the Stellar 32 campus within Geneva’s ZIPLO, the newly expanded facility will co-locate primary European operations of both companies. KBI Biopharma’s

The post JSR Life Sciences to expand KBI Biopharma and Selexis’ biologics manufacturing capabilities appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply